200 related articles for article (PubMed ID: 32744369)
1. Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study.
Kanokrungsee S; Pruettivorawongse D; Rajatanavin N
J Cosmet Dermatol; 2021 Mar; 20(3):812-818. PubMed ID: 32744369
[TBL] [Abstract][Full Text] [Related]
2. Comparative study between efficacy of Excimer light with topical Tacrolimus 0.1% versus excimer light with topical Bimatoprost 0.01% in treatment of facial Vitiligo.
Zaky MS; Atallah RB; El Abasy NTA; Elsaie ML
Arch Dermatol Res; 2024 Jun; 316(7):350. PubMed ID: 38850408
[TBL] [Abstract][Full Text] [Related]
3. Triple combination therapy of narrowband ultraviolet B, fractional carbon dioxide laser and topical bimatoprost 0.01% for non-segmental vitiligo on non-facial areas: A randomized half-body, double-blind, placebo-controlled, comparative study.
Kanokrungsee S; Khunkhet S; Rojhirunsakool S; Thadvibun K; Sahaspot T
Dermatol Ther; 2022 Jan; 35(1):e15198. PubMed ID: 34750933
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost ophthalmic solution in facial vitiligo.
Jha AK; Prasad S; Sinha R
J Cosmet Dermatol; 2018 Jun; 17(3):437-440. PubMed ID: 29034590
[TBL] [Abstract][Full Text] [Related]
5. Bimatoprost 0.03% Solution for the Treatment of Nonfacial Vitiligo.
Grimes PE
J Drugs Dermatol; 2016 Jun; 15(6):703-10. PubMed ID: 27272076
[TBL] [Abstract][Full Text] [Related]
6. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
Majid I
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
Lo YH; Cheng GS; Huang CC; Chang WY; Wu CS
J Dermatol; 2010 Feb; 37(2):125-9. PubMed ID: 20175845
[TBL] [Abstract][Full Text] [Related]
8. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo.
Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP
Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled study.
Nisticò S; Chiricozzi A; Saraceno R; Schipani C; Chimenti S
Photomed Laser Surg; 2012 Jan; 30(1):26-30. PubMed ID: 22054204
[TBL] [Abstract][Full Text] [Related]
11. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
[TBL] [Abstract][Full Text] [Related]
12. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study.
Kawalek AZ; Spencer JM; Phelps RG
Dermatol Surg; 2004 Feb; 30(2 Pt 1):130-5. PubMed ID: 14756638
[TBL] [Abstract][Full Text] [Related]
13. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.
Hartmann A; Bröcker EB; Hamm H
Acta Derm Venereol; 2008; 88(5):474-9. PubMed ID: 18779885
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.
Alshiyab D; Ba-Shammakh SA; Al-Fakih A; Tashman O; Sarakbi D; Al-Qarqaz F; Muhaidat J; Atwan A; Cork MJ
J Dermatolog Treat; 2024 Dec; 35(1):2296851. PubMed ID: 38124534
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study.
Silpa-Archa N; Likittanasombat S; Apinuntham C; Pruksaeakanan C; Charoenpipatsin N; Chaiyabutr C; Wongpraparut C
Sci Rep; 2023 Apr; 13(1):6438. PubMed ID: 37081101
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus Tacrolimus 0.1% ointment versus Tacrolimus 0.1% ointment in the treatment of stable vitiligo.
Shah B; Godse K; Mahajan S; Grandhi S; Shendkar S; Sharma A; Teli C; Pathak R; Parsad D
Dermatol Ther; 2019 Nov; 32(6):e13109. PubMed ID: 31600833
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases.
Silverberg NB; Lin P; Travis L; Farley-Li J; Mancini AJ; Wagner AM; Chamlin SL; Paller AS
J Am Acad Dermatol; 2004 Nov; 51(5):760-6. PubMed ID: 15523355
[TBL] [Abstract][Full Text] [Related]
19. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
[TBL] [Abstract][Full Text] [Related]
20. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
